30 Oct 24
Welcome to tranScrip’s monthly newsletter where we share with you the latest news and views from across the organisation.
This edition includes:
Dear Readers,
Welcome to the October edition of tranScrip’s newsletter! As we embrace the changing season, I am proud to share our latest updates, industry insights, and the incredible progress we are making together. Our growth over the past year is a testament to the hard work and dedication of our teams, who consistently go above and beyond to enable our clients to maximise the value of their products for the benefits of patients worldwide.
In this edition, you’ll find highlights of our new team members, upcoming events, and our commitment to providing strategic expertise, therapeutic experience and operational excellence across the entire product lifecycle. I encourage you to explore these articles, as they reflect our dedication to collaboration and excellence.
Warm regards, Mark Corbett, CEO, tranScrip
We are delighted to announce two new additions to the tranScrip team.
Dr Kathryn Owen has joined us as Executive Medical Director in the Early Development Group. Kate brings 24 years of expertise as Pharmaceutical Physician, specialising in oncology and hemato-oncology. She has an outstanding record in early clinical development, steering projects from candidate drug selection to phase IIb trials.
In addition, Roz Sutton has been appointed Senior Director of Regulatory Affairs. With over 20 years of experience in Global Regulatory Affairs, Roz has held senior leadership roles at renowned companies such as Roche and GSK, as well as in regulatory consulting with DLRC. Her appointment reflects tranScrip’s commitment to strengthening our regulatory team as we expand our expertise and service offerings.
ADCs are emerging as a promising approach to targeting cancer with precision, by linking a cytotoxic drug to an antibody specific to cancer cells. Top pharmaceutical companies are making headlines with successful ADC approvals. Recent clinical successes and new ADCs entering the market are fuelling interest.
If you’re interested in learning more about antibody-drug conjugates, Phil Barrington provides a comprehensive overview of this innovative class of therapeutics, exploring their mechanisms of action, benefits, and the latest developments in the field in this article > read here.
The rise of AMR is a major concern, with the pharmaceutical industry being pressured to develop new antibiotics. However, lack of financial incentives and regulatory challenges have made antibiotic R&D a difficult area. Push-pull mechanisms, public-private partnerships, and governmental initiatives are key in addressing this crisis.
We have a lineup of exciting conferences and events scheduled for November, and we cannot wait to connect with both familiar faces and new contacts. These gatherings provide a fantastic opportunity for meaningful discussions, knowledge sharing, and exploring the latest industry trends. If you will be attending any of these events, please let us know – we would love to reconnect!
Our team is looking forward to attending Bio-Europe in Stockholm next week. tranScrip’s Chief Executive Officer, Mark Corbett and BD Director, Inigo Montes are excited to connect with fellow professionals and explore new opportunities. If you’re attending, let’s meet up and discuss potential collaborations > schedule a meeting.
This year at The Future of UK Life Sciences Regulation 2024, BIA have introduced a valuable new feature for participants: one-on-one Regulatory Clinics with tranScrip’s experts, designed to offer tailored support for your unique regulatory challenges.
During refreshment breaks, our experts, Dr Jon Sisson, Roz Sutton and Karen Real, will be available to offer personalised guidance and strategic insights. Whether you are navigating a complex approval process or planning your next development steps, tranScrip’s team is here to support your progress and help you move forward with confidence.
If you are attending the conference you can book a regulatory clinic session here > secure your slot.
In keeping with the investment and dealmaking theme of Jefferies Week in London, this exclusive breakfast roundtable session hosted by EIP in partnership with tranScrip provides a chance for emerging company leaders to share their thoughts and concerns peer-to-peer around how to create and pitch their value proposition to investors and Pharma.
tranScrip’s Chief Scientific Officer, Linda Summerton, is looking forward to sharing her insights and facilitating this interactive roundtable discussion.
Registration: This event is designed for primary R&D biotech companies. Attendance is free of charge and by invitation only. To express your interest in attending, please contact alicia@onenucleus.com.
At tranScrip, our commitment to Environmental, Social, and Governance (ESG) principles is not just a responsibility; it is an integral part of our mission to foster a sustainable future and promote equity in healthcare. Our entire team is dedicated to making these initiatives a reality.
Key Achievements:
Looking ahead, we are excited to explore new initiatives that will further our ESG commitment.#
Thank you for reading this month’s edition of tranScrip’s newsletter. What insights resonated with you the most? Feel free to share your feedback with us.
To learn more about tranScrip’s services and how we can support you, connect with us.
Best regards, The tranScrip Team
Our experienced physicians and scientists, together with our regulatory, clinical and commercial experts can support you to maximise the value of your products. Whatever your project requires, we have the expertise to meet your needs.
